Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trialnews2026-04-27T11:30:28+00:00April 27th, 2026|Endpoints News|
Intellia’s in vivo CRISPR therapy first to succeed in Phase 3news2026-04-27T11:01:29+00:00April 27th, 2026|Endpoints News|
Veradermics wins at growing hair with oral Rogaine in first key test as a public companynews2026-04-27T11:00:29+00:00April 27th, 2026|Endpoints News|
AI biotech Fathom raises $47M Series A, renames from Atommapnews2026-04-27T11:00:07+00:00April 27th, 2026|Endpoints News|
Sun Pharma to buy Organon for $11.75B in major portfolio expansionnews2026-04-27T06:16:16+00:00April 27th, 2026|Endpoints News|
Investment in UK biotechs shows early signs of recovery, report saysnews2026-04-26T23:01:11+00:00April 26th, 2026|Endpoints News|
Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and morenews2026-04-25T10:00:19+00:00April 25th, 2026|Endpoints News|
FDA unveils three psychedelic-focused commissioner vouchersnews2026-04-24T17:26:49+00:00April 24th, 2026|Endpoints News|
Avalyn plots $182M IPO; WHO prequalifies Novartis’ malaria drugnews2026-04-24T15:03:27+00:00April 24th, 2026|Endpoints News|
Novartis pulls Pluvicto prostate cancer label expansion filing in the EUnews2026-04-24T14:49:37+00:00April 24th, 2026|Endpoints News|
